Transcranial Ultrasound in Clinical SONothrombolysis "TUCSON"

Terminated

Phase 1/2 Results

Summary of Purpose

This is a randomized, placebo controlled, parallel group dose escalation trial to evaluate the safety, tolerability, and activity of four sequential dose tiers of MRX-801 and ultrasound as an adjunctive therapy to tissue plasminogen activator (tPA) treatment in subjects with acute ischemic stroke. Trial Stopped: Sponsor decision

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 11 April 2008.

1 Dec 2006 18 Jul 2007 Unavailable 1 Mar 2008 1 Apr 2008 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Basics

Interventions

Conditions

Sponsors

Trial Design

  • Allocation: Randomized
  • Masking: Single Blind
  • Purpose: Treatment
  • Endpoint: Safety/Efficacy Study
  • Intervention: Parallel Assignment

Contacts

  • Brad Zakes President and CEO ImaRx Therapeutics, Inc. Phone: +1-520-770-1259

    bzakes@imarx.com